ScoreHaematology

International Prognostic Scoring System for Waldenström macroglobulinaemia (ISSWM)

Classifies patients with Waldenström macroglobulinaemia starting treatment into low, intermediate or high risk.

Updated 31 October 2026

When to use it

Patients with symptomatic Waldenström macroglobulinaemia at the start of first-line therapy.

What it needs

  • Age > 65 yearsYes or no
  • Haemoglobin ≤ 11.5 g/dLYes or no
  • Platelets ≤ 100 × 10⁹/LYes or no
  • β2-microglobulin > 3 mg/LYes or no
  • Serum monoclonal protein > 7.0 g/dLYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

The result is read in its clinical context; the app shows it with its units and warnings.

In the app it also calculates: ISSWM risk group.

Practical tip

Age > 65 years weighs more than the rest: on its own it places the patient at intermediate risk even with no other factors.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top